## Abdullah Pandor

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8403231/publications.pdf

Version: 2024-02-01

59 papers	1,777 citations	24 h-index	276875 41 g-index
59	59	59	2983
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technology Assessment, 2007, 11, 1-160, iii-iv.	2.8	311
2	Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and metaâ€analysis of randomized controlled trials. Journal of Internal Medicine, 2009, 265, 568-580.	6.0	183
3	Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review. Health Technology Assessment, 2004, 8, iii, 1-121.	2.8	144
4	Remote monitoring after recent hospital discharge in patients with heart failure: a systematic review and network meta-analysis. Heart, 2013, 99, 1717-1726.	2.9	114
5	Clinical decision rules for children with minor head injury: a systematic review. Archives of Disease in Childhood, 2011, 96, 414-421.	1.9	83
6	Clinical Decision Rules for Adults With Minor Head Injury: A Systematic Review. Journal of Trauma, 2011, 71, 245-251.	2.3	55
7	Febuxostat for the Management of Hyperuricaemia in Patients with Gout. Pharmacoeconomics, 2011, 29, 133-140.	3.3	54
8	Prehospital Noninvasive Ventilation for Acute Respiratory Failure: Systematic Review, Network Metaâ€analysis, and Individual Patient Data Metaâ€analysis. Academic Emergency Medicine, 2014, 21, 960-970.	1.8	52
9	Sepsis: the LightCycler SeptiFast Test MGRADE®, SepsiTest™ and IRIDICA BAC BSI assay for rapidly identifying bloodstream bacteria and fungi – a systematic review and economic evaluation. Health Technology Assessment, 2016, 20, 1-246.	2.8	52
10	Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation. Health Technology Assessment, 2008, 12, iii, xi-xiii, 1-212.	2.8	43
11	Pre-hospital non-invasive ventilation for acute respiratory failure: a systematic review and cost-effectiveness evaluation. Health Technology Assessment, 2015, 19, 1-102.	2.8	43
12	Telemonitoring after discharge from hospital with heart failure: cost-effectiveness modelling of alternative service designs. BMJ Open, 2013, 3, e003250.	1.9	41
13	Delphi consensus reached to produce a decision tool for SelecTing Approaches for Rapid Reviews (STARR). Journal of Clinical Epidemiology, 2019, 114, 22-29.	5.0	37
14	Risk assessment models for venous thromboembolism in hospitalised adult patients: a systematic review. BMJ Open, 2021, 11, e045672.	1.9	37
15	Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK. Current Medical Research and Opinion, 2005, 21, 101-112.	1.9	36
16	Bevacizumab for Metastatic Colorectal Cancer. Pharmacoeconomics, 2012, 30, 1119-1132.	3.3	35
17	The safety of intravitreal bevacizumab monotherapy in adult ophthalmic conditions: systematic review. BMJ Open, 2014, 4, e005244-e005244.	1.9	31
18	The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation. Health Technology Assessment, 2006, 10, iii-iv, xi-xiv, 1-185.	2.8	31

#	Article	IF	CITATIONS
19	Sexual health risk reduction interventions for people with severe mental illness: a systematic review. BMC Public Health, 2015, 15, 138.	2.9	30
20	The use of rapid review methods in health technology assessments: 3 case studies. BMC Medical Research Methodology, 2016, 16, 108.	3.1	30
21	Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2015, 33, 833-847.	3.3	27
22	Pharmacological thromboprophylaxis to prevent venous thromboembolism in patients with temporary lower limb immobilization after injury: systematic review and network metaâ€analysis. Journal of Thrombosis and Haemostasis, 2020, 18, 422-438.	3.8	27
23	Thromboprophylaxis in lower limb immobilisation after injury (TiLLI). Emergency Medicine Journal, 2020, 37, 36-41.	1.0	25
24	Diagnostic accuracy of prehospital triage tools for identifying major trauma in elderly injured patients: A systematic review. Journal of Trauma and Acute Care Surgery, 2021, 90, 403-412.	2.1	25
25	Diagnostic Accuracy of Clinical Characteristics for Identifying CT Abnormality after Minor Brain Injury: A Systematic Review and Meta-Analysis. Journal of Neurotrauma, 2012, 29, 707-718.	3.4	24
26	Economics of tandem mass spectrometry screening of neonatal inherited disorders. International Journal of Technology Assessment in Health Care, 2006, 22, 321-326.	0.5	20
27	Individual risk factors predictive of venous thromboembolism in patients with temporary lower limb immobilization due to injury: a systematic review. Journal of Thrombosis and Haemostasis, 2019, 17, 329-344.	3.8	19
28	Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: Results of a Markov model for UK costs using data registries. Clinical Therapeutics, 2008, 30, 1508-1523.	2.5	17
29	Cost Effectiveness of Ezetimibe in Patients with Cardiovascular Disease and Statin Intolerance or Contraindications. American Journal of Cardiovascular Drugs, 2008, 8, 419-427.	2.2	17
30	The effectiveness of sexual health interventions for people with severe mental illness: a systematic review. Health Technology Assessment, 2014, 18, 1-74.	2.8	17
31	Different strategies for pharmacological thromboprophylaxis for lower-limb immobilisation after injury: systematic review and economic evaluation. Health Technology Assessment, 2019, 23, 1-190.	2.8	17
32	Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews. Health Technology Assessment, 2018, 22, 1-294.	2.8	16
33	GENE EXPRESSION PROFILING AND EXPANDED IMMUNOHISTOCHEMISTRY TESTS TO GUIDE SELECTION OF CHEMOTHERAPY REGIMENS IN BREAST CANCER MANAGEMENT: A SYSTEMATIC REVIEW. International Journal of Technology Assessment in Health Care, 2017, 33, 32-45.	0.5	12
34	Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2018, 36, 29-38.	3.3	12
35	EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties. Applied Health Economics and Health Policy, 2018, 16, 429-432.	2.1	12
36	The Cost-Effectiveness of Expanding the UK Newborn Bloodspot Screening Programme to Include Five Additional Inborn Errors of Metabolism. International Journal of Neonatal Screening, 2020, 6, 93.	3.2	11

#	Article	IF	CITATIONS
37	Management of isolated minor head injury in the UK. Emergency Medicine Journal, 2010, 27, 856-859.	1.0	7
38	Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2017, 35, 415-424.	3.3	7
39	Ponatinib for Treating Acute Lymphoblastic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2018, 36, 759-768.	3.3	5
40	Are intensive lipid-lowering regimens an optimal economic strategy in patients with ACS? An acute and chronic perspective. Expert Review of Pharmacoeconomics and Outcomes Research, 2009, 9, 423-433.	1.4	4
41	The Cost-Effectiveness of Expanding the Nhs Newborn Bloodspot Screening Programme To Include Homocystinuria (Hcu), Maple Syrup Urine Disease (Msud), Glutaric Aciduria Type 1 (Ga1), Isovaleric Acidaemia (Iva), and Long-Chain Hydroxyacyl-Coa Dehydrogenase Deficiency (Lchadd). Value in Health, 2014, 17, A531.	0.3	3
42	Clinical-effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: A systematic review. International Journal of Technology Assessment in Health Care, 2005, 21, 150-150.	0.5	2
43	Rivaroxaban for Preventing Atherothrombotic Events in People with Acute Coronary Syndrome and Elevated Cardiac Biomarkers: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2016, 34, 463-477.	3.3	2
44	Ponatinib for Treating Chronic Myeloid Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2018, 36, 903-915.	3.3	2
45	Remote monitoring strategies for patients with stable Heart failure: a systematic review and Network meta-analysis. Value in Health, 2015, 18, A248.	0.3	1
46	OP106 The Impact Of Searching Fewer Databases In Health Technology Assessment Rapid Reviews. International Journal of Technology Assessment in Health Care, 2017, 33, 49-50.	0.5	1
47	VP166 Selecting Rapid Review Methods For Health Technology Assessment. International Journal of Technology Assessment in Health Care, 2017, 33, 225-226.	0.5	1
48	Decisionâ€analysis modelling of the effects of thromboprophylaxis for people with lower limb immobilisation for injury. British Journal of Haematology, 2019, 186, 166-168.	2.5	1
49	Cost-effectiveness modelling of telemonitoring after discharge from hospital with heart failure. International Journal of Integrated Care, 2013, 13, .	0.2	1
50	PMD2 Clinical Decision Rules for Adults with Minor Head injury: A Systematic Review. Value in Health, 2011, 14, A244.	0.3	0
51	PMD3 Biochemical Markers for the Identification of Intracranial Injury Following Minor Head injury: A Systematic Review and Meta-Analysis. Value in Health, 2011, 14, A244.	0.3	0
52	PMD5 Diagnostic Accuracy of Clinical Characteristics following Minor Head injury: A Systematic review and Meta-analysis. Value in Health, 2011, 14, A245.	0.3	0
53	Diagnosis and management of minor head injury in the UK. Journal of Paramedic Practice: the Clinical Monthly for Emergency Care Professionals, 2011, 3, 418-423.	0.1	0
54	029 Clinical decision rules for children with minor head injury: a systematic review. Emergency Medicine Journal, 2011, 28, A13-A13.	1.0	0

#	Article	IF	CITATIONS
55	Febuxostat per il trattamento dell'iperuricemia in pazienti affetti da gotta. Pharmacoeconomics Italian Research Articles, 2012, 14, 47-54.	0.2	0
56	PMD84 Telemonitoring After Discharge With Heart Failure - Cost-Effectiveness Modelling of Alternative Service Designs. Value in Health, 2012, 15, A360.	0.3	0
57	Obinutuzumab with Bendamustine for Treating Follicular Lymphoma Refractory to Rituximab: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2018, 36, 1143-1151.	3.3	0
58	Reply to Thromboprophylaxis in temporary lower limb immobilization: Extrapolate with care. Journal of Thrombosis and Haemostasis, 2020, 18, 519-520.	3.8	0
59	Individual risk factors predictive of major trauma in pre-hospital injured older patients: a systematic review. British Paramedic Journal, 2022, 6, 26-40.	0.8	0